TCT 2006 O Washington DC

Contemporary Outcome in Carotid Stenting (and CEA) Predictive Variables and Risk Benefit Considerations

K. Mathias Department of Radiology Teaching Hospital of Dortmund - Germany Statistics - the only science that enables different experts using the same figures to draw different conclusions

Evan Esar (1899-1995)


Evidence for treating ...

symptomatic patients
asymptomatic patients
the 'high-risk' patient

The International CEA Trials

ECST	surgical	medical	ARR	NNT	CVE prevented
	risk (%)	risk (%)	(%)	(%)	per 1000 CEAs
<30%	9.8 at 5y	3.9 at 5y	-5.9		
30-49%	10.2 at 5y	8.2 at 5y	-2.0		
50-69%	15.0 at 5y	12.1 at 5y	-2.9		
70-99%	10.5 at 5y	19.0 at 5y	+8.5	12	83 at 5y
NASCET	surgical	medical	ARR	NNT	CVE prevented
	risk (%)	risk (%)	(%)	(%)	per 1000 CEAs
30-49%	14.9 at 5y	18.7 at 5y	+3.8		
50-69%	15.7 at 3y	22.2 at 3y	+6.5	15	67 at 3y
70-99%	8.9 at 3y	28.3 at 3y	+19.4	5	200 at 3y

The International CEA Trials



CETC

Carotid Endarterectomy Trialists Collaboration

- combined <u>ALL</u> of the data from ECST, NASCET & VA
- 5,893 patients in database
- 33,000 patient years follow-up
- all angiograms reanalysed using NASCET method



<u>ipsilateral stroke at 5 years</u> including operative risk

stenosis	CEA	BMT	ARR	NNT	CVE/1000
<30%	12.05%	9.78%	-2.2%	-	-
30-49%	14.78%	18.06%	3.2%	31	32
50-69%	13.61%	18.18%	4.6%	21	46
70-99%	10.36%	26.24%	15.9%	6	159
near occlusion	16.82%	15.15%	-1.7%	-	_



<u>Ipsilateral stroke at 5 years</u> including operative risk

stenosis	CEA	BMT	ARR	NNT	CVE/1000
<30%	12.05%	9.78%	-2.2%	-	-
30-49%	14.78%	18.06%	3.2%	31	32
50-69%	13.61%	18.18%	4.6%	21	46
70-99%	10.36%	26.24%	15.9%	6	159
near occlusion	16.82%	15.15%	-1.7%	-	-

AHA Guidelines 2006

For patients with TIA or ischemic stroke within the last six months and ipsilateral severe (70-99%) stenosis, CEA by a surgeon with a peri-operative morbidity/mortality of <6% is recommended. (Class I, Evidence level A)

Circulation 2006;37:577-617

AHA Guidelines 2006

For patients with TIA or ischaemic stroke within the last six months and ipsilateral severe (70-99%) stenosis, CEA *by a surgeon with a perioperative morbidity/mortality of <6%* is recommended. (Class I, Evidence Level A)

For patients with TIA or ischaemic stroke within the last six months and ipsilateral moderate (50-69%) stenosis, CEA is recommended, <u>depending</u> on patient specific factors such as age, gender, comorbidity and severity of initial symptom. (Class I, Evidence Level A)

Circulation 2006;37:577-617



<u>Ipsilateral stroke at 5 years</u> including operative risk

stenosis	CEA	BMT	ARR	NNT	CVE/1000	
<30%	12.05%	9.78%	-2.2%		-	
	40.040/	40.400/	4.00/	04	40	
50-69%	13.61%	18.18%	4.6%	21	46	
70-99%	10.36%	26.24%	15.9%	6	D9	
near occlusion			954 unnecessary			
	16.82%	15.15%	-1.7%	procedures		

Take-home Messages

The assumption that <u>all</u> patients have the <u>same</u> risk/ benefit is flawed

achieving maximum benefit: -incremental stenosis


-age
-rapid intervention
-gender
-plaque morphology
-contralateral
occlusion
-operative risk


Take-home Messages


The assumption that <u>all</u> patients have the <u>same</u> risk/ benefit is flawed


achieving maximum benefit: -incremental stenosis

-age
-rapid intervention
-gender
-plaque morphology
-contralateral
occlusion
-operative risk









Conclusion

You cannot treat symptomatic patients with '50-99% stenoses' as being a homogenous group of equal risk.


Take-home Messages

The assumption that <u>all</u> patients have the <u>same</u> risk/ benefit is flawed


achieving maximum benefit: -incremental stenosis

-age
-rapid intervention
-gender
-plaque morphology
-contralateral
occlusion
-operative risk


Effect of Age on Benefit from CEA



Effect of Age on Benefit from CEA




Effect of Age on Benefit from CEA



Effect of Age on Benefit from CAS

Stroke rates increase with age



adapted from ProCAS, Lennox Hill etc.

Conclusion

The general feeling that elderly patients do not gain significant benefit because of an increased procedural risk is unsustainable. They have the most to gain! But CAS must keep the 6% limit!!!


Take-home Messages

The assumption that <u>all</u> patients have the <u>same</u> risk/ benefit is flawed

achieving maximum benefit: -incremental stenosis

-age
-rapid intervention
-gender
-plaque morphology
-contralateral
occlusion
-operative risk

Rapid Tx of Symptomatic Patients



time from last event to randomisation

adapted from Rothwell 2004

Conclusion

Every third stroke is a second stroke! ICA stenosis should be treated as early as reasonably possible, regardless of the invasive method used.

Take-home Messages


The assumption that <u>all</u> patients have the <u>same</u> risk/ benefit is flawed

achieving maximum benefit: -incremental stenosis

-age
-rapid intervention
-gender
-plaque morphology
-contralateral
occlusion
-operative risk

Gender, Delay & Stenosis Severity


Strokes prevented/1000 CEAs at 5 years



CETC Lancet 2005

Gender, Delay & Stenosis Severity

Strokes prevented/1000 CEAs at 5 years



CETC Lancet 2005

Conclusion

It is an uncomfortable observation that unless women with moderate stenoses receive treatment within a month of symptoms, they gain little benefit but face all the risks. They should not be considered 'high-risk'

Take-home Messages

The assumption that <u>all</u> patients have the <u>same</u> risk/ benefit is flawed

achieving maximum benefit: -incremental stenosis


-age
-rapid intervention
-gender
-plaque morphology
-contralateral
occlusion
-operative risk

Influence of Plaque Morphology

smooth stenosis




ulcerated stenosis



A confers benefit in ulcerated steno

ipsilateral strokes prevented/1000 CEAs at 2 years



Conclusion

There has been much debate about the merits of studying plaque morphology. A simple assessment of whether the surface is irregular or smooth could have immense predictive benefit.

Take-home Messages

The assumption that <u>all</u> patients have the <u>same</u> risk/ benefit is flawed

achieving maximum benefit: -incremental stenosis


-age
-rapid intervention
-gender
-plaque morphology
-contralateral ICA
occlusion
-operative risk

Stenosis & Contralateral Occlusion



Effect of Contralateral Disease


No of ipsilateral strokes prevented per 1000 CEAs at 2 years



NASCET 1995

Effect of Contralateral Disease

No of ipsilateral strokes prevented per 1000 CEAs at 2 years



Conclusion

In parallel with plaque irregularity, the presence of contralateral occlusion is the single biggest predictor of benefit from intervention. NASCET stroke risk of 14.7% much higher than with CAS (~5%)!

Take-home Messages


The assumption that <u>all</u> patients have the <u>same</u> risk/ benefit is flawed

achieving maximum benefit: -incremental stenosis

-age
-rapid intervention
-gender
-plaque morphology
-contralateral
occlusion
-operative risk


Effect of 30-d Risk on Outcome

CVEs prevented at 5 years per 1000 patients



Effect of 30-d Risk on Outcome

CVEs prevented at 5 years per 1000 patients



Conclusion

No surgeon or interventionist can justify offering treatment on the basis of the International Trials if his procedural risks are out of accepted guidelines. Personal audit is mandatory.

Evidence for treating ...

symptomatic patients
asymptomatic patients
the 'high-risk' patient



	5 year s surgery			RRR	NNT	CVE/ 1000
ACAS (n=1662)	5.1%	11.0%	5.9%	54%	17	59



Criticisms of ACAS

- disabling/fatal stroke <u>not</u> reduced
- ACAS observed <u>no</u> significant benefit in women
- patients had to live 5 years to gain benefit
- stroke reduction only achieved in year five
- concerns over surgeon selection
- no association between stenosis severity & stroke risk
- no association between bilateral disease & stroke risk

ACAS & ACST Findings


	5 year str surgery	oke risk BMT	ARR	RRR	NNT	CVE/ 1000
ACAS (n=1662)	5.1%	11.0%	5.9%	54%	17	59
ACST (n=3120)	6.4%	11.8%	5.4%	46%	19	53

ACAS, 1995 ACST, 2004

Principle Messages from ACST

- maximum benefit in patients aged <75 years</p>
- no evidence of benefit in patients aged >75 yrs
- 'apparent' benefit for men and women
- 50% reduction in disabling/fatal stroke

Benefit in Women?



ACAS, 1995 ACST, 2004

P.M. Rothwell Lancet 2004

Benefit in Women?

You cannot ignore the obvious fact that women gained less benefit from intervention than men. Treatment should probably be reserved for women aged <70 years with no significant co-morbidity. Asymptomatic females could never be considered 'high-risk'

Evidence for treating ...

symptomatic patients
asymptomatic patients
the 'high-risk' patient

Evidence for treating ...

"When carotid endarterectomy is not feasible in high-risk patients and carotid stenting is, patients should undergo stenting <u>regardless</u> of the medical risk"

Alhaddad

AHA Guidelines

Among patients with a severe (>70%) symptomatic stenosis in whom the stenosis is difficult to access surgically, major medical conditions are present, or other specific circumstances exist (e.g. radiation arteritis, recurrent stenosis), CAS is not inferior to CEA and may be considered, provided CAS is performed with established peri-procedural risks of 4-6%.

Class IIa, Evidence Level B

Opinion or Evidence?

"Registries of carotid stenting in patients at high risk for CEA are consistent with the SAPPHIRE trial. Patients who have serious co-morbid medical or anatomical conditions that increase the risk from an open surgical approach or general anaesthesia should be primary candidates for carotid stenting"

G. Roubin Circulation 2006

Do we have enough data to make this recommendation?



SAPPHIRE

723 'high risk' patients considered for inclusion

general criteria: symptomatic + stenosis >50% asymptomatic + stenosis >80%

'high-risk' criteria - significant cardiac disease

- severe pulmonary disease
- contralateral occlusion
- contralateral RLN palsy
- previous neck surgery
- radiation arteritis
- recurrent stenosis
- age >80 years

NEJM 2004;351:1493

me Interventions are Obviously High-ris



'High-risk' for what, exactly?

high risk plaque symptomatic

high risk patient cardiac disease pulmonary disease >80 years high risk procedure contralat occlusion rec laryngeal N palsy PMH neck surgery radiation arteritis recurrent stenosis

'High-risk' for what, exactly?

high risk plaque symptomatic	high risk patient cardiac disease	high risk procedure contralat occlusion	
	pulmona <mark>ry d</mark> isease	rec laryngeal N palsy	
	>80 year	PMH neck surgery	
		radiation arteritis	
		recurrent stenosis	

It is difficult, based on *evidence*, to place **'asymptomatic'** patients within any of these categories

Unexplained Paradoxes

Based on evidence, will CAS prevent stroke?

	symptomatic	asymptomatic
aged >75 years	+++	0
with plaque irregularity	+++	0
incremental stenosis	+++	0
with contralateral occlusion+	***	0

based on data from ECST, NASCET, ACAS, ACST, SPACE, and SAPPHIRE



71% of the randomised patients were <u>asymptomatic</u>

in whom:

30 day death/strokefollowing angioplasty = 5.8%following surgery= 6.1%

NEJM 2004;351:1493


Conclusions from SAPPHIRE

So, a trial where 70%+ were asymptomatic and in whom there was a 6% procedural risk and in whom you will

<u>never</u>

confer any long term benefit in stroke prevention has been used to develop guidelines for all high-risk patients i.e. including all the symptomatic ones!


Strokes Prevented per 1000 CEAs



"high relative risk/benefit group"

	CVE prevented
patient subgroup	per 1000 CEAs
SAPPHIRE asymp with 6% risk	22 at 5y
symp, 70-99% aged >75 years	333 at 2y
symp, 70-99% with high co-morbidity	333 at 2y
symp, 70-99% recurrent TIAs for >6 mt	ns 333 at 2y
symp, 70-99% with operations <2 week	s 333 at 3y
symp, 80-99% with intracranial disease	333 at 3y
symp, 90-99% with no string sign	370 at 3y
symp, 70-99%, with contralateral occlus	sion 500 at 2y
symp, 90-99% with plaque ulceration	500 at 2y

What in whom?





We have still a lot of unanswered questions

Parting message.....

Irrespective of any debate about which asymptomatic patient should be treated, whether CEA or CAS is safer, how and by whom CAS should be performed, ALL pale into insignificance compared with the effect of delay in treating symptomatic patients with severe carotid artery disease.